Dr. Reddy's Laboratories Limited (FRA:RDDA)

Market Cap	9.30B -27.3%
Revenue (ttm)	3.28B +11.1%
Net Income	536.36M +5.4%
EPS	0.64 +5.6%
Shares Out	n/a
PE Ratio	17.33
Forward PE	21.49
Dividend	0.06 (0.53%)
Ex-Dividend Date	Jul 25, 2025

Volume	n/a
Average Volume	263
Open	10.90
Previous Close	10.90
Day's Range	10.90 - 10.90
52-Week Range	10.20 - 13.80
Beta	n/a
RSI	38.15
Earnings Date	Jan 21, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 27,811
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RDDA

Financial Performance

In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.

Financial numbers in INR